222 related articles for article (PubMed ID: 27106409)
1. Is there a role for early chemotherapy in the management of pituitary adenomas?
Lin AL; Sum MW; DeAngelis LM
Neuro Oncol; 2016 Oct; 18(10):1350-6. PubMed ID: 27106409
[TBL] [Abstract][Full Text] [Related]
2. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
4. Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.
Matsuno A; Murakami M; Hoya K; Yamada SM; Miyamoto S; Yamada S; Son JH; Nishido H; Ide F; Nagashima H; Sugaya M; Hirohata T; Mizutani A; Okinaga H; Ishii Y; Tahara S; Teramoto A; Osamura RY
Med Mol Morphol; 2014 Mar; 47(1):1-7. PubMed ID: 23955641
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
6. Treatment of pituitary neoplasms with temozolomide: a review.
Syro LV; Ortiz LD; Scheithauer BW; Lloyd R; Lau Q; Gonzalez R; Uribe H; Cusimano M; Kovacs K; Horvath E
Cancer; 2011 Feb; 117(3):454-62. PubMed ID: 20845485
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
8. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
9. Atypical, invasive, recurring Crooke cell adenoma of the pituitary.
Rotondo F; Cusimano M; Scheithauer BW; Coire C; Horvath E; Kovacs K
Hormones (Athens); 2012; 11(1):94-100. PubMed ID: 22450349
[TBL] [Abstract][Full Text] [Related]
10. Use of temozolomide in aggressive pituitary tumors: case report.
Mohammed S; Kovacs K; Mason W; Smyth H; Cusimano MD
Neurosurgery; 2009 Apr; 64(4):E773-4; discussion E774. PubMed ID: 19349807
[TBL] [Abstract][Full Text] [Related]
11. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide and pituitary adenoma.
Hueng DY; Ma HI; Sytwu HK; Liu MY
J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
[No Abstract] [Full Text] [Related]
14. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
Dillard TH; Gultekin SH; Delashaw JB; Yedinak CG; Neuwelt EA; Fleseriu M
Pituitary; 2011 Mar; 14(1):80-91. PubMed ID: 20972839
[TBL] [Abstract][Full Text] [Related]
15. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
16. HIF-1α Inhibition Sensitized Pituitary Adenoma Cells to Temozolomide by Regulating Presenilin 1 Expression and Autophagy.
Kun Z; Yuling Y; Dongchun W; Bingbing X; Xiaoli L; Bin X
Technol Cancer Res Treat; 2016 Dec; 15(6):NP95-NP104. PubMed ID: 26647409
[TBL] [Abstract][Full Text] [Related]
17. Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
Donovan LE; Arnal AV; Wang SH; Odia Y
CNS Oncol; 2016 Oct; 5(4):203-9. PubMed ID: 27615706
[TBL] [Abstract][Full Text] [Related]
18. Treatment of pituitary neoplasms with temozolomide: A review.
Marucci G
Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
[No Abstract] [Full Text] [Related]
19. Aggressive Pituitary Adenomas: The Dark Side of the Moon.
Priola SM; Esposito F; Cannavò S; Conti A; Abbritti RV; Barresi V; Baldari S; Ferraù F; Germanò A; Tomasello F; Angileri FF
World Neurosurg; 2017 Jan; 97():140-155. PubMed ID: 27713064
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
